Increased antibody response after SARS-CoV-2 mRNA-based vaccination in rituximab-treated patients with previous COVID-19 infection

Rheumatology (Oxford). 2022 Jun 28;61(SI2):SI191-SI193. doi: 10.1093/rheumatology/keac201.
No abstract available

MeSH terms

  • Antibody Formation
  • COVID-19* / prevention & control
  • Humans
  • RNA, Messenger
  • Rituximab / therapeutic use
  • SARS-CoV-2*
  • Vaccination

Substances

  • RNA, Messenger
  • Rituximab